Conditions: Down Syndrome
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 23
Healthy volunteers: no

Brief summary:
This is a prospective, randomized, double-blind, placebo-controlled, parallel-group, three-arm, multicenter study of the safety and PK of ELND005 administered orally for 4 weeks. This study will enroll Down Syndrome patients 18 to 45 years of age (inclusive) without dementia.

Detailed description:

Arms:
arm 1: ELND005 250 mg BID arm 2: ELND005 250 mg QD arm 3: Placebo BID

Interventions: intervention 1: ELND005 intervention 2: Placebo
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: